Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.

[1]  M. Nishino,et al.  An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  C. Lucchesi,et al.  CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Bhasin,et al.  Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E , 2017, Oncotarget.

[4]  N. Myall,et al.  Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy , 2017, The oncologist.

[5]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[6]  I. Soubeyran,et al.  Clinical impact of extensive molecular profiling in advanced cancer patients , 2017, Journal of Hematology & Oncology.

[7]  John G Doench,et al.  ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. , 2017, Cell reports.

[8]  E. Martínez-Balibrea,et al.  Resistant mechanisms to BRAF inhibitors in melanoma. , 2016, Annals of translational medicine.

[9]  Sourav Bandyopadhyay,et al.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer , 2014, Proceedings of the National Academy of Sciences.

[10]  C. Rudin,et al.  Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  C. Swanton,et al.  Cancer chromosomal instability: therapeutic and diagnostic challenges , 2012, EMBO reports.